| Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape KR McCarthy, LJ Rennick, S Nambulli, LR Robinson-McCarthy, WG Bain, ... Science 371 (6534), 1139-1142, 2021 | 576 | 2021 |
| Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections RK Shields, BA Potoski, G Haidar, B Hao, L Chen, EG Press, ... Clinical Infectious Diseases 63 (12), 1615-1618, 2016 | 429 | 2016 |
| Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance G Haidar, NJ Philips, RK Shields, D Snyder, S Cheng, BA Potoski, Y Doi, ... Clinical Infectious Diseases 65 (1), 110-120, 2017 | 258 | 2017 |
| Effect of convalescent plasma on organ support–free days in critically ill patients with COVID-19: a randomized clinical trial H Abdelhady, M Abdelrazik, Z Abdi, D Abdo, A Abdulle, L Abel, ... Jama 326 (17), 1690-1702, 2021 | 190 | 2021 |
| Mutations in blaKPC-3 That Confer Ceftazidime-Avibactam Resistance Encode Novel KPC-3 Variants That Function as Extended-Spectrum β-Lactamases G Haidar, CJ Clancy, RK Shields, B Hao, S Cheng, MH Nguyen Antimicrobial agents and chemotherapy 61 (5), 10.1128/aac. 02534-16, 2017 | 181 | 2017 |
| Phage Therapy of Mycobacterium Infections: Compassionate Use of Phages in 20 Patients With Drug-Resistant Mycobacterial Disease RM Dedrick, BE Smith, M Cristinziano, KG Freeman, D Jacobs-Sera, ... Clinical infectious diseases 76 (1), 103-112, 2023 | 142 | 2023 |
| Identifying spectra of activity and therapeutic niches for ceftazidime-avibactam and imipenem-relebactam against carbapenem-resistant Enterobacteriaceae G Haidar, CJ Clancy, L Chen, P Samanta, RK Shields, BN Kreiswirth, ... Antimicrobial agents and chemotherapy 61 (9), 10.1128/aac. 00642-17, 2017 | 137 | 2017 |
| Severe acute respiratory syndrome coronavirus 2 viremia is associated with coronavirus disease 2019 severity and predicts clinical outcomes JL Jacobs, W Bain, A Naqvi, B Staines, PMS Castanha, H Yang, VF Boltz, ... Clinical Infectious Diseases 74 (9), 1525-1533, 2022 | 113* | 2022 |
| Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients M Agha, M Blake, C Chilleo, A Wells, G Haidar MedRxiv, 2021 | 102 | 2021 |
| Cytomegalovirus infection in solid organ and hematopoietic cell transplantation: state of the evidence G Haidar, M Boeckh, N Singh The Journal of infectious diseases 221 (Supplement_1), S23-S31, 2020 | 100 | 2020 |
| Intractable coronavirus disease 2019 (COVID-19) and prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in a chimeric antigen receptor-modified T … MK Hensley, WG Bain, J Jacobs, S Nambulli, U Parikh, A Cillo, B Staines, ... Clinical Infectious Diseases 73 (3), e815-e821, 2021 | 96 | 2021 |
| Fever of unknown origin G Haidar, N Singh New England Journal of Medicine 386 (5), 463-477, 2022 | 89 | 2022 |
| Long-term (180-day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial S Florescu, D Stanciu, M Zaharia, A Kosa, D Codreanu, A Kidwai, ... Jama 329 (1), 39-51, 2023 | 81 | 2023 |
| Metagenomic identification of severe pneumonia pathogens in mechanically-ventilated patients: a feasibility and clinical validity study L Yang, G Haidar, H Zia, R Nettles, S Qin, X Wang, F Shah, SF Rapport, ... Respiratory research 20, 1-12, 2019 | 74 | 2019 |
| Changing trends in mortality among solid organ transplant recipients hospitalized for COVID‐19 during the course of the pandemic MR Heldman, OS Kates, K Safa, CN Kotton, SJ Georgia, JM Steinbrink, ... American journal of transplantation 22 (1), 279-288, 2022 | 73 | 2022 |
| Suboptimal response to coronavirus disease 2019 messenger RNA vaccines in patients with hematologic malignancies: a need for vigilance in the postmasking era ME Agha, M Blake, C Chilleo, A Wells, G Haidar Open forum infectious diseases 8 (7), ofab353, 2021 | 72 | 2021 |
| Invasive mold infections after chimeric antigen receptor–modified T-cell therapy: a case series, review of the literature, and implications for prophylaxis G Haidar, K Dorritie, R Farah, T Bogdanovich, MH Nguyen, P Samanta Clinical Infectious Diseases 71 (3), 672-676, 2020 | 70 | 2020 |
| Impact of bamlanivimab monoclonal antibody treatment on hospitalization and mortality among nonhospitalized adults with severe acute respiratory syndrome coronavirus 2 infection JR Bariola, EK McCreary, RJ Wadas, KE Kip, OC Marroquin, T Minnier, ... Open forum infectious diseases 8 (7), ofab254, 2021 | 66 | 2021 |
| Viral infections in solid organ transplant recipients: novel updates and a review of the classics G Haidar, N Singh Current opinion in infectious diseases 30 (6), 579-588, 2017 | 66 | 2017 |
| COVID-19: challenges of viral variants JL Jacobs, G Haidar, JW Mellors Annual Review of Medicine 74, 31-53, 2023 | 60 | 2023 |
